Fluorescent In Situ Hybridization Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Fluorescent In Situ Hybridization Market is segmented By Product Type (Analytical Instrument, Kits & Reagents, Software & Services), By Application and Geography.

Fluorescent In Situ Hybridization Market Snapshot

Fluorescent In Situ Hybridization Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The fluorescent in situ hybridization market is expected to propel due to the high prevalence of diseases like cancer and genetic disorders. According to the World Health Organization, currently, around 10,000 and more of the disease are monogenetic. Monogenetic disease refers to the modification of a single gene. Furthermore, cancer is one of the leading causes of death and 9.6 million people have died from it worldwide in 2017, according to the World Health Organization. Also, emerging trends in products are expected to propel the market growth. For instance, in 2018, Sysmex Corporation launched a fluorescent in situ hybridization testing software system for research purposes. Hence, these factors are expected to boost the demand for fluorescent in situ hybridization.

Scope of the Report

Fluorescent In Situ Hybridization (FISH) mainly used for diagnostic purposes, involves fluorescent probes that bind to a nucleic acid that very well complements it. Fluorescent In Situ Hybridization Market is segmented By Product Type, By Application, and Geography.

By Product Type
Analytical Instrument
Kits & Reagents
Software & Services
By Application
Genetic Diseases
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cancer Segment is Expected to Show a Significant Growth in the Fluorescent In Situ Hybridization Market

• The growing presence of in vitro diagnostics and the increasing burden of cancer are expected to be a major factor for driving the market in this particular segment. Cytogenetic technique plays a crucial role in the detection of cancer chromosomal abnormalities. According to the World Health Organization, lung cancer is one of the major diagnosed cancer with 2.09 million cases globally, in 2018.

• Furthermore, according to the study of Public Literature of Science, fluorescent in situ hybridization is very effective in detecting the abnormalities of the MET (hepatocyte growth receptor factor) gene of non-small cell lung cancer. Thus, these factors are expected to impact positively on the cancer segment of the fluorescent in situ hybridization market.

Fluorescent In Situ Hybridization Market

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to be a dominant region in the fluorescence in situ hybridization market owing to the higher prevalence of chronic disease and growing product approvals related to FISH. For instance, in 2019, Oxford Gene Technology received a US FDA (Food & Drug Administration) approval for eight fish probes that would be involved in the detection of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). According to the American Cancer Society, the incidence of cancer in 2020 is estimated to be 1.8 million. Therefore, it is expected to boost the fluorescent in situ hybridization market growth.

Fluorescent In Situ Hybridization Market - Growth Rate by Region

Competitive Landscape

Strategic initiatives taken by companies is expected to fuel the fluorescent in situ hybridization market. For instance, in 2016, Agilent Technologies and Applied Spectral Imaging (ASI) collaborated to develop and market the FISH products of Agilent and imaging software of ASI. Some of the companies which are currently dominating the market are Abnova Corporation, Genemed Technologies, Inc., Biocare Medical, LLC, Qiagen (Exiqon A/S), Agilent Technologies, Merck KGaA, Biodot Inc., PERKINELMER Inc., ThermoFisher Scientific Inc., and F. HOFFMANN-LA ROCHE LTD.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Chronic Disease

      2. 4.2.2 Product Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness about Emerging Diagnostic Technologies in Cytogenetics

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product Type

      1. 5.1.1 Analytical Instrument

      2. 5.1.2 Kits & Reagents

      3. 5.1.3 Software & Services

    2. 5.2 By Application

      1. 5.2.1 Cancer

      2. 5.2.2 Genetic Diseases

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abnova Corporation

      2. 6.1.2 Agilent Technologies

      3. 6.1.3 Biocare Medical, LLC

      4. 6.1.4 Biodot Inc.

      5. 6.1.5 F. HOFFMANN-LA ROCHE LTD.

      6. 6.1.6 Genemed Technologies, Inc.

      7. 6.1.7 Merck KGaA

      8. 6.1.8 PERKINELMER INC

      9. 6.1.9 Qiagen (Exiqon A/S)

      10. 6.1.10 ThermoFisher Scientific Inc.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Fluorescent In Situ Hybridization Market market is studied from 2018 - 2026.

The Fluorescent In Situ Hybridization Market is growing at a CAGR of 6.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

ThermoFisher Scientific Inc. , Agilent Technologies , Genemed Technologies Inc. , PERKINELMER Inc., F. HOFFMANN-LA ROCHE LTD. are the major companies operating in Fluorescent In Situ Hybridization Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!